Cardiologists: What's the future for bioresorbable stents in the U.S.?

Absorb fully resorbable stent in its deployed state--Courtesy of Abbott

While partially bioresorbable stents have been available in Europe for a number of years, the first fully resorbable stent, Abbott’s ($ABT) Absorb, has only recently gained approval in the U.S. and Europe. And though there are many benefits to a stent that completely reabsorbs within two to three years, the technology’s novelty gives rise to several challenges, said a group of U.S. and European cardiologists at a roundtable discussion Thursday.

A resorbable stent is attractive for use in younger patients, who will have to live with coronary artery disease for many more years, noted Dr. Jeffrey Moses, director of the Center for Interventional Vascular Therapy at New York-Presbyterian Hospital/Columbia University Medical Center, and Dr. Michael Rinaldi, Medical Director of Clinical Research at Sanger Heart & Vascular Institute, on the call.

Stenting that does not leave a metal scaffold allows more freedom for follow-up procedures down the line. Bioresorbable stents would also perform well in patients with long arterial lesions, where a surgeon would otherwise “pave the entire vessel with stents,” raising the risk of late stent thrombosis, Rinaldi said.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

However, the panelists highlighted the steep learning curve that accompanies the Absorb, and noted surgeons’ familiarity with partially resorbable stents, and the preparation and post-procedure steps for these stents, as an advantage for the older technology.

The steep learning curve comes primarily from the thicker struts of the Absorb. Not only do they protrude more into the lumen than do partially resorbable models, but they also cover a greater proportion of the vessel wall when they are implanted, said Dr. Robert Byrne, a cardiologist at Deutsches Herzzentrum in Munich.

These differences require a different implantation technique, including more aggressive vessel preparation and post-procedure dilation, Byrne said. Surgeons are also encouraged to use intravascular ultrasound to help size the vessel and place the implant. All of these factors can add steps, time and cost to stenting procedures, potentially making a bioresorbable stent a less attractive option for healthcare providers.

With regards to cost, there is, as expected, a cost premium to a first-generation device such as said procedure for third-party payers and patients as well as for hospitals should also be considered, said Dr. Elizabeth Holper, chief clinical quality officer and medical director of Interventional Cardiology Research at The Heart Hospital Bayor Plano. But in the long term, cost will not likely remain a concern, Byrne said. If the U.S. follows Germany’s example, insurers will deem the technology a treatment worth funding and reimburse hospitals for it.

All in all, the panelists agreed that there is still insufficient data for physicians to make truly data-driven decisions involving bioresorbable stents. But “a plethora of data” should become available within the next year or two, and we should be on “much firmer ground” regarding the advantages and limitations of fully resorbable stents, Moses said.

With the recent FDA approvals of Abbott's Absorb and Boston Scientific's ($BSX) partially resorbable Synergy stent, the roundtable was presented by Boston Scientific to discuss what patients and physicians can expect from these new technologies. Boston Sci's Synergy is the first FDA-approved partially resorbable stent.

Related Articles:
FDA approves Abbott's Absorb, the first completely resorbable heart stent
Boston Scientific gets the first (partially) bioabsorbable stent to FDA approval
Bioresorbable stents: Abbott gets CE mark; Boston Sci reports Synergy data

Suggested Articles

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.

The company describes the continuous glucose monitor as the world’s smallest and thinnest diabetes sensor, with a disc about the size of two pennies.

Junshi’s PD-1 blocker is already approved in China for metastatic melanoma, but the Shanghai-based biotech may soon add throat cancer to its label.